Clinical trials: Acute Cardiovascular Disease
Stroke
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
The purpose of this study is to evaluate the safety and tolerability of SUN13837 and to determine whether SUN13837 improves the physical performance, relative to placebo, following an acute stroke in adult subjects.
- Trial name
- NCT02258880
- Testing
- SUN13837
- Where
- 53 sites in United States, Canada and 2 more
- Sponsor
- Daiichi Sankyo
Acute Ischemic Stroke
Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window (ImpACT-24A)
The primary objective of the study is to assess the safety and effectiveness of SPG stimulation with the ISS in patients with an acute ischemic stroke in the anterior circulation initiated within 24 hours from stroke onset.
- Trial name
- ImpACT-24A (NCT03767192)
- Testing
- Active Stimulation
- Where
- 8 sites in United States, Germany and 1 more
- Volunteers
- 327 people
- Sponsor
- BrainsGate
Acute Ischemic Stroke
A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)
The purpose of this study is to determine if YM872 in combination with t-PA can reduce disability and brain damage from stroke. YM872 or placebo will be given as a continuous intravenous (iv) infusion for 24 hours.
- Trial name
- NCT00044057
- Testing
- YM872 (zonampanel), t-PA (alteplase)
- Where
- 118 sites in United States, Austria and 3 more
- Sponsor
- Astellas Pharma Inc
Acute Coronary Syndrome (ACS)
Maintenance of Platelet Inhibition With Cangrelor
The purpose of this study is to demonstrate that patients receiving cangrelor infusion before coronary artery bypass grafting have an acceptable safety profile and can undergo surgery without excessive bleeding peri-operatively.
- Trial name
- Bridge (NCT00767507)
- Testing
- cangrelor
- Where
- United States
- Volunteers
- 221 people
- Sponsor
- The Medicines Company
Acute Coronary Syndrome
Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome
Prevention of cardiovascular events by antiplatelet agents after acute coronary syndrome
- Trial name
- AReMIS (NCT01952392)
- Where
- France
- Volunteers
- 4,992 people
- Sponsor
- AstraZeneca
Acute Ischemic Stroke
The Efficacy and Safety of HRS-4029 in Acute Ischemic Stroke Patients
This trial will evaluate the efficacy and safety of HRS-4029 compared with placebo in participants with acute ischemic stroke (AIS).
- Trial name
- NCT07739160
- Testing
- HRS-4029
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Cardiovascular Disorders
Ekvasis of Atorvastatin (Antorcin®) Treatment in Patients With Acute Cardiovascular Events
In western societies hypercholesterolemia is one of the major and independent factors that predispose to cardiovascular disease and death from them.
- Trial name
- EKVASIS (NCT01770210)
- Testing
- Patients on atorvastatin treatment
- Where
- 17 sites in Greece
- Volunteers
- 670 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Ischemic Stroke, Acute, Brain Diseases
Safety and Efficacy of SINOMED SR for Endovascular Treatment of Acute Ischemic Stroke
A prospective, multicenter, randomized controlled, non-inferiority study to investigate the effectiveness and safety of SINOMED SR for endovascular treatment of acute ischemic stroke
- Conditions
- Ischemic Stroke, Acute, Brain Diseases, Cerebrovascular Disorders
- Trial name
- NCT04973332
- Testing
- Intracranial thrombectomy stent
- Where
- 14 sites in China
- Volunteers
- 218 people
- Sponsor
- Sinomed Neurovita Technology Inc.
Acute Non-ST Elevation Myocardial Infarction
DLBS1033 for Acute NSTEMI Without Early Coronary Revascularization
This is a prospective, randomized, double-blind, double-dummy, and controlled study of DLBS1033 in the management of acute non-ST elevation myocardial infarction (NSTEMI) without early coronary revascularization.
- Trial name
- NCT02146664
- Testing
- DLBS1033
- Where
- 2 sites in Indonesia
- Sponsor
- Dexa Medica Group
Heart Failure, Respiratory Insufficiency
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
The purpose of this study is to evaluate the efficacy and safety of rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) events and VTE-related death post-hospital discharge in…
- Conditions
- Heart Failure, Respiratory Insufficiency, Stroke Acute, Infectious Diseases
- Trial name
- MARINER (NCT02111564)
- Testing
- Rivaroxaban, 10 mg, Rivaroxaban, 7.5 mg
- Where
- 593 sites in United States, Argentina and 35 more
- Volunteers
- 12,024 people
- Sponsor
- Janssen Research & Development, LLC
Acute Ischemic Stroke
Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke
This is a Phase II study to assess the safety and tolerability of DM199 in acute ischemic stroke patients. The study will be randomized, placebo controlled at multiple centers.
- Trial name
- ReMEDy1 (NCT03290560)
- Testing
- Recombinant human tissue kallikrein
- Where
- 12 sites in Australia
- Volunteers
- 92 people
- Sponsor
- DiaMedica Therapeutics Inc
Acute Stroke, Cerebral Infarction
ICTUS Study: International Citicoline Trial on Acute Stroke
Citicoline is a safe drug approved in some countries for the treatment of acute ischemic stroke. The drug has shown some evidence of efficacy in a pooled analysis, based on four clinical trials done in USA with oral…
- Trial name
- ICTUS (NCT00331890)
- Testing
- Citicoline
- Where
- 65 sites in Germany, Portugal and 1 more
- Volunteers
- 2,298 people
- Sponsor
- Ferrer Internacional S.A.
Acute Myocardial Infarction
Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction
This was a double-blind, randomized, placebo-controlled study that was designed to enroll a total of 225 participants with de novo anterior wall acute ST-segment elevation myocardial infarction (STEMI) due to a lesion of the left…
- Trial name
- AMICI (NCT01781390)
- Testing
- Mesenchymal Precursor Cells (MPC) 12.5 M, Mesenchymal Precursor Cells (MPC) 25 M
- Volunteers
- 106 people
- Sponsor
- Mesoblast, Inc.
Acute Coronary Syndrome (ACS)
Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)
This Phase IV, multicenter trial is designed to assess the efficacy of prasugrel in preventing the formation of blood clots in Taiwanese patients with ACS who have been treated with PCI.
- Trial name
- NCT03672097
- Testing
- Prasugrel
- Where
- 10 sites in Taiwan
- Volunteers
- 204 people
- Sponsor
- Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company
Acute Coronary Syndrome, Coronary Artery Stenosis
Use of Magnetocardiography in Evaluation of Patients Going for Cardiac Catheterization
This is a multicenter, prospective trial to measure the test performance characteristics of the Magnetocardiography (MCG) CardioFlux cardiac diagnostic system in detecting clinically significant coronary artery obstruction in…
- Conditions
- Acute Coronary Syndrome, Coronary Artery Stenosis, Myocardial Ischemia
- Trial name
- NCT04044391
- Testing
- CardioFlux Magnetocardiograph
- Where
- 2 sites in United States
- Volunteers
- 101 people
- Sponsor
- Genetesis Inc.
Acute Heart Failure, Congestive Heart Failure
Clinical Evaluation of the TRVD™ System in ADHF
A prospective, multi-national, open-label clinical study which is conducted to asses the safety, feasibility and performance of the TRVD™ System in hospital-admitted patients with Acute Decompensated Heart Failure (ADHF) and…
- Conditions
- Acute Heart Failure, Congestive Heart Failure, Heart Failure, Congestive
- Trial name
- TRVD (NCT03621436)
- Testing
- TRVD Therapy
- Where
- 3 sites in Belgium, Croatia and 1 more
- Volunteers
- 13 people
- Sponsor
- Magenta Medical Ltd.
Coronary Artery Diseases
BIOFLOW-III VIP Russia Registry Orsiro Stent System
Clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES). Along with it, an explanatory (hypothesis-finding) problem will be investigated, whether the patient's body…
- Trial name
- NCT02247492
- Where
- 7 sites in Russia
- Volunteers
- 200 people
- Sponsor
- Biotronik Russia
Acute Ischemic Stroke
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
The goal of this study is to evaluate the safety and efficacy of JX10 versus placebo in participants with Acute Ischemic Stroke (AIS) who present for care within 4.5 to 24 hours. The main question the study aims to answer are: 1.
- Trial name
- ORION (NCT06990867)
- Testing
- JX10
- Where
- 104 sites in United States, Belgium and 19 more
- Volunteers
- 740 people
- Sponsor
- Corxel Pharmaceuticals
Acute Coronary Syndrome
Study of LC23-1306 in Healthy Male Subjects
This will be a dose block-randomized, double-blind, active and placebo controlled, single and multiple dosing, dose-escalation study to evaluate tolerability, safety and pharmacokinetic/pharmacodynamic characteristics.
- Trial name
- NCT01526577
- Testing
- LC23-1306, Ticagrelor
- Where
- South Korea
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Acute Ischemic Stroke
UCMSCs as Treatment for Patients With Acute Ischemic Stroke (Stroke Neuroncell-EX)
The primary objective of this study is to evaluate the functional recovery based on Barthel index (BI) and modified Rankin Scale (mRS) while the secondary objectives are to assess the survival and re-admission rate as well as to…
- Trial name
- NCT06129175
- Testing
- Neuroncell-EX
- Where
- Malaysia
- Volunteers
- 80 people
- Sponsor
- Cytopeutics Sdn. Bhd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.